BioStem Technologies, Inc.

Wat BioStem Technologies, Inc. op 12 november 2026 rapporteerde

Uit de eigen 8-K van het bedrijf.

Wat het management zei

“We grew hospital revenue again this quarter, and importantly, are doing so by adding new accounts and increasing penetration with existing customers. The number of customers buying two or more of our product lines grew 14% from the second quarter. We also completed the final step of our commercial infrastructure build-out, and with in-house production of Neox and Clarix expected to begin in the first half of 2027, we are on track to become a fully vertically integrated company with those product lines,”

Letterlijk geciteerd uit het persbericht, en alleen getoond wanneer de deponering het aan een met naam genoemde persoon toeschrijft.

Hoe de koers reageerde

Publicaties komen voor de opening of na sluiting, dus het venster loopt van het slot vóór de publicatiedag tot het slot van de handelsdag erna — de reactie valt er in beide gevallen binnen.

Wat BioStem Technologies, Inc. doet

Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines. Join BioStem’s Distribution List & Social Media: To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE , and follow us on X and LinkedIn .

De eigen omschrijving van het bedrijf, zoals die onderaan het persbericht staat.